824 related articles for article (PubMed ID: 11041316)
1. The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents.
Dekeyne A; Brocco M; Adhumeau A; Gobert A; Millan MJ
Psychopharmacology (Berl); 2000 Sep; 152(1):55-66. PubMed ID: 11041316
[TBL] [Abstract][Full Text] [Related]
2. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.
Millan MJ; Hjorth S; Samanin R; Schreiber R; Jaffard R; De Ladonchamps B; Veiga S; Goument B; Peglion JL; Spedding M; Brocco M
J Pharmacol Exp Ther; 1997 Jul; 282(1):148-61. PubMed ID: 9223550
[TBL] [Abstract][Full Text] [Related]
3. The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis.
Millan MJ; Gobert A; Roux S; Porsolt R; Meneses A; Carli M; Di Cara B; Jaffard R; Rivet JM; Lestage P; Mocaer E; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Oct; 311(1):190-203. PubMed ID: 15146031
[TBL] [Abstract][Full Text] [Related]
4. Roles of 5-HT(1A) receptors in the dorsal raphe and dorsal hippocampus in anxiety assessed by the behavioral effects of 8-OH-DPAT and S 15535 in a modified Geller-Seifter conflict model.
Cervo L; Mocaër E; Bertaglia A; Samanin R
Neuropharmacology; 2000 Apr; 39(6):1037-43. PubMed ID: 10727714
[TBL] [Abstract][Full Text] [Related]
5. Effect of WAY-100135 on the hippocampal acetylcholine release potentiated by 8-OH-DPAT, a serotonin1A receptor agonist, in normal and p-chlorophenylalanine-treated rats as measured by in vivo microdialysis.
Nakai K; Fujii T; Fujimoto K; Suzuki T; Kawashima K
Neurosci Res; 1998 May; 31(1):23-9. PubMed ID: 9704975
[TBL] [Abstract][Full Text] [Related]
6. Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of midazolam and 5-HT1A receptor agonists.
Stefański R; Pałejko W; Bidziński A; Kostowski W; Płaźnik A
Neuropharmacology; 1993 Oct; 32(10):977-85. PubMed ID: 7905194
[TBL] [Abstract][Full Text] [Related]
7. The 5HT(1A) receptor ligand, S15535, antagonises G-protein activation: a [35S]GTPgammaS and [3H]S15535 autoradiography study.
Newman-Tancredi A; Rivet J; Chaput C; Touzard M; Verrièle L; Millan MJ
Eur J Pharmacol; 1999 Nov; 384(2-3):111-21. PubMed ID: 10611431
[TBL] [Abstract][Full Text] [Related]
8. Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT ipsapirone and buspirone in the rat.
Schreiber R; De Vry J
Eur J Pharmacol; 1993 Nov; 249(3):341-51. PubMed ID: 7904566
[TBL] [Abstract][Full Text] [Related]
9. Serotonin 5-HT
Depoortère R; Bardin L; Varney MA; Newman-Tancredi A
ACS Chem Neurosci; 2019 Jul; 10(7):3101-3107. PubMed ID: 30929419
[TBL] [Abstract][Full Text] [Related]
10. Characterization of MDL 73005EF as a 5-HT1A selective ligand and its effects in animal models of anxiety: comparison with buspirone, 8-OH-DPAT and diazepam.
Moser PC; Tricklebank MD; Middlemiss DN; Mir AK; Hibert MF; Fozard JR
Br J Pharmacol; 1990 Feb; 99(2):343-9. PubMed ID: 1970269
[TBL] [Abstract][Full Text] [Related]
11. Estimation of apparent pA2 values for WAY 100635 at 5-HT1A receptors regulating 5-hydroxytryptamine release in anaesthetised rats.
Assié MB; Koek W
Eur J Pharmacol; 2000 Dec; 409(2):173-7. PubMed ID: 11104831
[TBL] [Abstract][Full Text] [Related]
12. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists.
Meller E; Goldstein M; Bohmaker K
Mol Pharmacol; 1990 Feb; 37(2):231-7. PubMed ID: 1968223
[TBL] [Abstract][Full Text] [Related]
13. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.
Koek W; Patoiseau JF; Assié MB; Cosi C; Kleven MS; Dupont-Passelaigue E; Carilla-Durand E; Palmier C; Valentin JP; John G; Pauwels PJ; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1998 Oct; 287(1):266-83. PubMed ID: 9765347
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of MP349, a novel 5-HT1A-receptor antagonist with anxiolytic-like activity, in mice and rats.
Wesołowska A; Paluchowska MH; Gołembiowska K; Chojnacka-Wójcik E
J Pharm Pharmacol; 2003 Apr; 55(4):533-43. PubMed ID: 12803776
[TBL] [Abstract][Full Text] [Related]
15. Bidirectional modulation of classical fear conditioning in mice by 5-HT(1A) receptor ligands with contrasting intrinsic activities.
Youn J; Misane I; Eriksson TM; Millan MJ; Ogren SO; Verhage M; Stiedl O
Neuropharmacology; 2009; 57(5-6):567-76. PubMed ID: 19607850
[TBL] [Abstract][Full Text] [Related]
16. On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635.
Collinson N; Dawson GR
Psychopharmacology (Berl); 1997 Jul; 132(1):35-43. PubMed ID: 9272757
[TBL] [Abstract][Full Text] [Related]
17. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.
Millan MJ; Brocco M; Gobert A; Dekeyne A
Psychopharmacology (Berl); 2005 Feb; 177(4):448-58. PubMed ID: 15289999
[TBL] [Abstract][Full Text] [Related]
18. Development of a presynaptic 5-HT1A antagonist.
Mattson RJ; Catt JD; Sloan CP; Gao Q; Carter RB; Gentile A; Mahle CD; Matos FF; McGovern R; VanderMaelen CP; Yocca FD
Bioorg Med Chem Lett; 2003 Jan; 13(2):285-8. PubMed ID: 12482441
[TBL] [Abstract][Full Text] [Related]
19. Gestational manganese intoxication and anxiolytic-like effects of diazepam and the 5-HT1A receptor agonist 8-OH-DPAT in male Wistar rats.
Kwieciński A; Nowak P
Pharmacol Rep; 2009; 61(6):1061-8. PubMed ID: 20081241
[TBL] [Abstract][Full Text] [Related]
20. Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions.
Gobert A; Rivet JM; Cistarelli L; Melon C; Millan MJ
Neuroscience; 1999; 93(4):1251-62. PubMed ID: 10501449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
